Published in Clinical Oncology Week, July 5th, 2004
"Our purpose was to study the risk factors associated with disease progression after high-dose chemotherapy followed by autologous stem cell transplantation in patients with recurrent or refractory Hodgkin's lymphoma (HL). We analyzed the long-term outcome of 184 patients with recurrent or refractory HL who underwent autologous hematopoietic stem cell transplantation," scientists in the United States report.
"At the time of transplantation," wrote U. Popat and coworkers, "82 patients were in first relapse or second remission, 46 patients were refractory to the primary...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Oncology Week